Skip to main content
. 2015 Jun 20;26(9):2347–2353. doi: 10.1007/s00198-015-3129-7

Table 5.

Relative risk reduction (RRR, %) between treatments (teriparatide versus placebo) for morphometric vertebral fractures at different T-score values of BMD

Percentile BMD RRR
Estimate 95 % CI
10th −3.7 49 % 0–86 %a
25th −3.3 73 % 17–81 %
50th −2.8 88 % 50–97 %
75th −2.4 94 % 57–99 %
90th −2.0 97 % 61–100 %

a95 % CI relative risk fracture teriparatide versus placebo = 0.14–1.81